In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Fractyl Health, Inc., with a price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Ulz has given his Buy rating due to a combination of factors, primarily focusing on Fractyl Health, Inc.’s promising clinical data and strategic advancements. The company has reported sustained glucose control and weight stabilization in patients from the Revita German Real-World Registry Study, with notable results extending up to two years post-procedure. This durability in outcomes is a positive indicator for the company’s future data updates and potential market success.
Additionally, Fractyl Health is on track with its pivotal Revita data, expected in the second half of 2026, and has plans to file for approval based on these results. The company’s financial position, with $77.7 million in cash, is projected to support operations into early 2027, further strengthening its investment appeal. The anticipation of positive Phase 3 Revita results and the progress in their gene therapy program for type 2 diabetes also contribute to the optimistic outlook and the Buy rating.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $5.00 price target.
GUTS’s price has also changed moderately for the past six months – from $1.710 to $1.130, which is a -33.92% drop .